Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7-H3 CAR-T in Recurrent or Refractory Glioblastoma
NCT04077866Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BCB-276 in glioblastoma (GBM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Status: unknown.
02
Drugs
BCB-276
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04077866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077866.